Physician profile
Edwin L Cueva
NPI 1952319261
$19,573.93
in general payments reported to CMS, 2019-2025
20 companies · $5,014 in 2025
The $5,014 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $615 · 2021: $2,883 · 2022: $2,554 · 2023: $4,285 · 2024: $3,765 · 2025: $5,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,817.64 |
| Education | $245.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $3,505.30 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $2,969.80 | 2020-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $2,437.19 | 2021-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $2,063.18 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,917.60 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $1,752.05 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $1,123.47 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $1,029.05 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $825.25 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $803.56 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $374.35 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $285.75 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $160.50 | 2021-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $81.93 | 2023 | Quviviq |
| Indivior INC. | $64.10 | 2021-2024 | Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $48.25 | 2025 | Tonmya |
| Almatica Pharma LLC | $45.66 | 2022-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $38.62 | 2021 | |
| Allergan, INC. | $26.72 | 2020 | |
| Eisai INC. | $21.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Cueva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.